Ascendis Pharma A/S
Research Ascendis Pharma A/S (ASND) on Bullrun: market cap USD 15.05B, P/E 17.5. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerASND
- ExchangeNASDAQ
- CountryDenmark
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 15.05B
- P/E17.5
- Financial periodQ2 2026
- RevenueEUR 339.29M
- Net incomeEUR 206.97M
- Free cash flowEUR 270.73M
- Gross margin91.8%
Valuation Snapshot
latest market cap is USD 15.05B; P/E is 17.5.
Peer valuation comparison
Latest P/E is 17.47x versus a Healthcare sector median of 24.61x (29.0% below).
Latest P/E is 17.47x versus a Denmark median of 17.65x.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 720.13M | -EUR 228.03M | EUR 45.41M | 86.8% | -3.76 | EUR 616.04M | EUR 871.79M | -EUR 162.82M |
| FY2024 | EUR 363.64M | -EUR 378.08M | -EUR 307.62M | 87.8% | -6.53 | EUR 559.54M | EUR 856.62M | -EUR 105.71M |
| FY2023 | EUR 266.72M | -EUR 481.45M | -EUR 469.80M | 83.4% | -8.55 | EUR 392.16M | EUR 644.27M | -EUR 145.70M |
| FY2022 | EUR 51.17M | -EUR 583.19M | -EUR 510.19M | 76.3% | -10.4 | EUR 444.77M | EUR 508.38M | EUR 263.35M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 15.05B | 17.5 | n/a | n/a |
| 2025 | 2025-12-31 | USD 13.09B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 8.24B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.13B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 6.96B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 7.64B | n/a | n/a | n/a |
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
ETFs that hold Ascendis Pharma A/S
Ascendis Pharma A/S is one of the ten largest holdings of 2 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| Harbor Health Care UCITS ETF - Accumulating | 9.62% | 0.89% |
| First Trust Ipox Europe Equity Opportunities UCITS ETF | 5.40% | 0.65% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ascendis Pharma A/S's market cap?
Ascendis Pharma A/S's market capitalization is USD 15.05B.
What is Ascendis Pharma A/S's P/E ratio?
Ascendis Pharma A/S's price-to-earnings (P/E) ratio is 17.5.
What does Ascendis Pharma A/S do?
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.